X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA JUBILANT LIFE SCIENCES GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 19.4 14.6 132.4% View Chart
P/BV x 3.4 4.6 74.2% View Chart
Dividend Yield % 0.3 0.4 77.8%  

Financials

 GLENMARK PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-14
GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs930187 497.9%   
Low Rs51765 794.8%   
Sales per share (Unadj.) Rs322.6364.3 88.5%  
Earnings per share (Unadj.) Rs28.56.8 416.2%  
Cash flow per share (Unadj.) Rs39.224.5 160.0%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.32.4 11.6%  
Book value per share (Unadj.) Rs183.0164.9 111.0%  
Shares outstanding (eoy) m282.17159.28 177.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.3 648.9%   
Avg P/E ratio x25.418.4 138.1%  
P/CF ratio (eoy) x18.55.1 359.2%  
Price / Book Value ratio x4.00.8 517.8%  
Dividend payout %7.043.8 16.0%   
Avg Mkt Cap Rs m204,20620,061 1,017.9%   
No. of employees `00013.76.2 221.8%   
Total wages/salary Rs m18,71811,052 169.4%   
Avg. sales/employee Rs Th6,636.89,383.0 70.7%   
Avg. wages/employee Rs Th1,364.71,786.9 76.4%   
Avg. net profit/employee Rs Th586.1176.3 332.4%   
INCOME DATA
Net Sales Rs m91,03158,034 156.9%  
Other income Rs m914191 479.5%   
Total revenues Rs m91,94558,224 157.9%   
Gross profit Rs m16,1545,786 279.2%  
Depreciation Rs m3,0192,812 107.4%   
Interest Rs m2,8563,237 88.2%   
Profit before tax Rs m11,193-72 -15,524.7%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m3,155696 453.0%   
Profit after tax Rs m8,0391,090 737.2%  
Gross profit margin %17.710.0 178.0%  
Effective tax rate %28.2-965.9 -2.9%   
Net profit margin %8.81.9 470.0%  
BALANCE SHEET DATA
Current assets Rs m69,88729,280 238.7%   
Current liabilities Rs m32,87938,912 84.5%   
Net working cap to sales %40.7-16.6 -245.0%  
Current ratio x2.10.8 282.5%  
Inventory Days Days8184 96.5%  
Debtors Days Days9351 184.5%  
Net fixed assets Rs m28,89255,712 51.9%   
Share capital Rs m282155 182.7%   
"Free" reserves Rs m51,35320,968 244.9%   
Net worth Rs m51,63526,265 196.6%   
Long term debt Rs m41,41817,169 241.2%   
Total assets Rs m125,95488,606 142.2%  
Interest coverage x4.91.0 503.2%   
Debt to equity ratio x0.80.7 122.7%  
Sales to assets ratio x0.70.7 110.3%   
Return on assets %8.64.9 177.1%  
Return on equity %15.64.2 375.0%  
Return on capital %15.111.6 130.5%  
Exports to sales %037.8 0.0%   
Imports to sales %016.5 0.0%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs mNA9,567 0.0%   
Fx inflow Rs m36,31722,004 165.0%   
Fx outflow Rs m9,72011,749 82.7%   
Net fx Rs m26,59810,255 259.4%   
CASH FLOW
From Operations Rs m16,4818,026 205.3%  
From Investments Rs m-10,133-1,744 581.0%  
From Financial Activity Rs m-4,685-4,447 105.3%  
Net Cashflow Rs m1,7701,834 96.5%  

Share Holding

Indian Promoters % 48.3 45.6 105.9%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 6.9 8.7 79.3%  
FIIs % 34.4 21.2 162.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.1 49.8%  
Shareholders   56,727 23,815 238.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Higher, Oil Prices, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed volatility during closing hours yesterday and ended their day marginally higher.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

Sensex Nearing All-Time Highs: Stocks to Buy in this Rally(Profit Hunter)

Mar 14, 2019

The BSE Sensex is heating up. In just a few days, the benchmark index is up 3%. Is this rally sustainable? Richa finds out...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Mar 22, 2019 09:25 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS